ProCE Banner Activity

Myeloid Malignancies Clinical Advances Journal Club on Emerging Data for MDS: Answers to Frequently Asked Questions

Clinical Thought

A commentary covering frequently asked questions from healthcare professionals related to emerging clinical data for patients with low-risk, intermediate-risk, and high-risk MDS.

Released: July 22, 2024

Expiration: July 21, 2025

Share

Faculty

Courtney DiNardo

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb

Bristol Myers Squibb

Disclosure

Primary Author

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, GlaxoSmithKline, Notable Labs, Rigel, Schrödinger, Servier; researcher: AbbVie, Astex, Bristol Myers Squibb, Foghorn, Jazz, Schrödinger, Servier.

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has no relevant financial relationships to disclose.